A previous post summarized the favorable results from a study of the probiotic, Bifidobacterium infantis 35624 in patients with irritable bowel syndrome (IBS). Medscape has a review of IBS that includes a favorable assessment of the role of Bifidobacterium infantis 35624.

The author, Dr. Philip Schoenfeld from the University of Michigan concludes that tegaserod (Zelnorm) is the treatment of choice.

His thoughts regarding Bifidobacterium infantis 35624.

• Available information supports its role as complementary treatment for patients with IBS that is not responding to first-line treatment
• The appropriate duration of treatment is not known
• It is not known if symptoms return after treatment
• There are no important safety issues (so far)

9/19/06 22:26 JR